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Abstract 
Prior studies demonstrated increased plasma immunoglobulin E (IgE) in diabetic patients, 
but the direct participation of IgE in diabetes or obesity remains unknown. This study 
found that plasma IgE levels correlated inversely with body weight, body mass index, 
and body fat mass among a population of randomly selected obese women. IgE receptor 
FcεR1-deficient (Fcer1a–/–) mice and diet-induced obesity (DIO) mice demonstrated that 
FcεR1 deficiency in DIO mice increased food intake, reduced energy expenditure, and 
increased body weight gain, but improved glucose tolerance and glucose-induced insulin 
secretion. White adipose tissue (WAT) from Fcer1a–/– mice showed increased expression 
of phospho-AKT, C/EBPα, PPARγ, Glut4, and Bcl-2, but reduced UCP1 and phospho-
JNK expression, tissue macrophage accumulation, and apoptosis, suggesting that IgE 
reduces adipogenesis and glucose uptake, but induces energy expenditure, adipocyte 
apoptosis, and WAT inflammation. In 3T3-L1 cells, IgE inhibited the expression of 
C/EBPα and PPARγ, and preadipocyte adipogenesis, and induced adipocyte apoptosis. 
IgE reduced 3T3-L1 cell expression of Glut4, phospho-AKT, and glucose uptake, which 
concurred with improved glucose tolerance in Fcer1a–/– mice. This study established two 
novel pathways of IgE in reducing body weight gain in DIO mice by suppressing 
adipogenesis and inducing adipocyte apoptosis, while worsening glucose tolerance by 
reducing Glut4 expression, glucose uptake, and insulin secretion. 
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Introduction 
Immunoglobulin E (IgE) activates mast cells by binding to its high affinity receptor Fcε 
receptor-1 (FcεR1). This activity of IgE is essential to allergic responses (1), such as 
asthma. Recent studies demonstrated that IgE also activates macrophages and T cells (2, 
3). All these IgE-targeting cells play detrimental roles in obesity and diabetes (4-6), 
suggesting the participation of IgE in these metabolic diseases. Although the direct role 
of IgE in obesity and diabetes remains untested, asthma associates with increased plasma 
IgE (7) and acts as an important risk factor of obesity and diabetes. Of 4,773 subjects 
aged 20 and older randomly selected from 10,348 individuals from 2005 to 2006 in the 
National Health and Nutrition Examination Survey (NHANES) in the United States, IgE 
concentrations correlated positively with obesity risk but not insulin resistance in 
asthmatic patients (8). Of 4,321 children aged 2 to 19 from the same population, obese 
and overweight children had higher plasma total IgE levels, driven largely by allergic 
sensitivity to foods (9). A respective study of 246 adults with asthma and other atopic 
disorders revealed that asthmatic patients had higher body mass indices (BMI) than non-
asthmatics. Obesity associated with increased serum IgE among those patients (10). Yet 
in a population study of 666 patients with severe asthma, plasma IgE levels correlated 
negatively with BMI (11). These studies therefore do not prove the direct participation of 
IgE in body weight gain. Previous studies investigated IgE in patients and animals with 
diabetes. A linear regression analysis of a population study of 340 patients aged 55 to 75 
revealed a positive correlation between plasma IgE and type-2 diabetes mellitus and pre-
diabetes status. Ordinal logistic regression demonstrated that plasma IgE correlates with 
the incidence of type-2 diabetes before and after adjusting for common diabetes risk 
	   4 
factors (12, 13). In non-obese diabetic (NOD) mice, anti-FcεR1 antibody therapy 
activated basophils and MCs, but delayed type 1 diabetes (14). These observations from 
diabetic patients and mice highlight the role of IgE in diabetes.  
This study design was twofold: to test the direct role of IgE in obesity and 
diabetes using FcεR1-deficient Fcer1a–/– mice in diet-induced obese and diabetic mice; 
and to understand the molecular and cellular mechanism by which this immunoglobulin 
molecule contributes to these metabolic diseases. 
Materials and Methods 
Patients 
A random selection from a bariatric surgery program from the Institute of 
Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital (Paris, France) 
yielded a cohort of 50 Caucasian women with morbid obesity. These patients met the 
criteria for bariatric surgery (BMI ≥ 40 kg/m2, or ≥ 35 kg/m2 with at least one 
comorbidity: hypertension, type-2 diabetes, dyslipidemia, or obstructive sleep apnea 
syndrome), but without allergic or autoimmune diseases or anti-allergy and anti-
autoimmunity medications that may affect plasma IgE levels. Subjects had stable weights 
(±3 kg) for at least 3 months before the surgery. Of the 50 patients, 18 (36 %) had type 2 
diabetes as defined by a fasting glycemia >7 mmol/L and/or the use of an anti-diabetic 
drug. The ethics committees of the CPP Ile de France 1 (number 0611351) approved the 
clinical investigations. All subjects gave written informed consent. Spearman’s 
correlation test helped test the correlation between plasma IgE concentration and clinical 
and biological parameters at baseline. Patient body composition was determined by dual-
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energy X-ray absorptiometry (DEXA, Hologic, Bedford, MA). Blood samples were 
obtained before the bariatric surgery after 12 hours of fasting to measure total cholesterol, 
high-density lipoprotein (HDL) cholesterol, triglycerides, insulin, glucose, hemoglobin 
(HbA1c), leptin, adiponectin, inflammatory markers (highly sensitive C-reactive protein 
(hs-CRP) and interleukin-6 (IL6), and IgE as previously described (12, 13, 15, 16). 
 
Mice 
We used C57BL/6 (Jackson Laboratory, Bar Harbor, ME) and Fcer1a–/– mice (C57BL/6, 
N9) (2, 3). All mice used in this study were littermates. Males (or female) mice at 6 
weeks of age from each group were fed a high-fat diet (HFD, D12492: 60 kcal% fat, 
Research Diets Inc. New Brunswick, NJ) for 17 weeks. Mouse body weight was 
monitored weekly. After 17 weeks on a HFD, mouse total body fat and lean masses were 
assessed by dual energy X-ray absorptiometry (DEXA; PIXImus, Fitchburg, WI). For 
calorimetric analysis, these mice were placed individually in an indirect open circuit 
calorimeter (Oxymax System; Columbus Instruments, Columbus, OH). Oxygen and 
carbon dioxide concentrations by volume were monitored at the inlet and outlet parts of a 
partially sealed chamber, through which a known flow of ambient air was forcibly 
ventilated. The concentration difference measured between the parts was used to compute 
oxygen consumption (VO2) and carbon dioxide production (VCO2). The consumption 
and production information were presented in units of ml/kg/h and normalized to 25 °C 
and 760 mmHg. Food intake was investigated by using the Oxymax Feed Scale Device 
(Columbus Instruments) for three continuous days and data were presented as the average 
food intake per day of the last two days without considering the first day acclimation 
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period. The physical activity of the mice was monitored with OPTO-M3 Activity 
Application Device (Columbus Instruments). The movements (other than scratching, 
grooming, digging, etc.) of each animal were determined by infrared beams in x, y, and z 
axes. After 17 weeks on a HFD, an intraperitoneal glucose tolerance test (1.5 g 
glucose/kg body weight) and an insulin tolerance test (ITT) (1.5 U/kg body weight) were 
also performed after an overnight (16 hours) and daytime 5-hour fast, respectively. Mice 
were sacrificed and fat tissue was collected. Mice were bred and maintained according to 
the Guide for the Care and Use of Laboratory Animals published by the National 
Institutes of Health. Harvard Medical School Standing Committee on Animals approved 
all animal protocols. 
 
Cell culture  
3T3-L1 (ATCC, CL-173) cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Life Technologies, Woburn, MA) including 10% calf serum and L-glutamine. 
To induce adipogenesis, complete confluent 3T3-L1 cells were cultured in induction 
media containing DMEM (Life Technologies), 10% fetal bovine serum, L-glutamine, 
MEM sodium pyruvate, 0.0115 g/ml 3-isobutyl-1-methylxanthine (IBMX; Sigma, St. 
Louis, MO), 1 mM dexamethasone (Sigma), and 167 µM insulin (Sigma) for 2 days and 
for additional 6 days without IBMX and dexamethasone. 
 
Islet isolation and glucose-stimulated insulin secretion (GSIS) by islets 
Islets were isolated from 2-month-old male C57BL/6J mice (Jackson Laboratory) by the 
intraductal collagenase digestion method, as described previously (17). For GSIS assay, 
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after culturing for 12 hours in RPMI 1640 medium containing 5.6 mM glucose and 
supplemented with 10% fetal calf serum, ten size-matched islets were incubated at 37°C 
for 1.5 hours in Krebs-Ringer bicarbonate buffer containing 2.8, 8.3 or 22.2 mM glucose 
with or without IgE (0.01, 0.1, 1, 10, 100 µg/ml). The insulin levels in the culture media 
were measured using an insulin ELISA kit (Crystal Chem Inc., Downers Grove, IL). 
FcεR1α mRNA levels were measured in total RNA extracted from 50 islets that were 
incubated at 37°C for 24 hours in RPMI 1640 medium containing 5.6 mM glucose with 
10% fetal calf serum in the presence or absence of IgE (0.01, 0.1, 1, 10, 100 µg/ml ). 
Each quantitative reaction was performed in duplicate. 
 
Quantitative real-time PCR  
Total RNA was extracted from WAT, 3T3-L1 cells, bone marrow-derived macrophages, 
or islets using a Qiagen RNA extraction kit (Qiagen, Valencia, CA). Quantified total 
RNA using Nanodrop 2000 (Thermo Fisher Scientific Inc., Waltham, MA) was 
transcribed into first strand cDNA using Superscript First Strand kit (Life Technologies). 
Real-time PCR (RT-PCR) was performed using SYBR green super mix (Bio-Rad) in 
Bio-Rad iCycler iQ to determine the mRNA levels of C/EBPα, PPARγ, and three FcεR1 
chains (α, β, and γ) using 36B4 (acidic ribosomal phosphoprotein PO) and β-actin as 
internal controls to normalize gene expression. RT-PCR data was analyzed based on delta 
delta CT calculation and presented as the fold of change obtained from the value of 2^(-
∆∆CT). All RT-PCR primer sequences are listed in Supplementary Table 1. 
 
Immunoblotting and immunohistochemistry  
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WAT, brown adipose tissue (BAT), and cells were lysed in a RIPA buffer containing 50 
mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS, proteinase 
inhibitor (Roche Diagnostics Corporation, Indianapolis, IN), and phosphatase inhibitor 
cocktail (Roche). Tissue lysates were centrifuged at 20,000 xg for 15 min. Supernatant 
was removed without interrupting the upper layer fat for protein concentration 
determination using the DC protein assay kit (Bio-Rad, Hercules, CA). Tissue or cell 
lysate was separated by SDS-PAGE, blotted, and detected with different antibodies, 
including FcεR1a, glucose transporter-4 (Glut4), Bcl-2, p-JNK, total JNK, p-AKT, total 
AKT, CCAAT/enhancer binding protein-α (CEBPα), peroxisome proliferator-activated 
receptor-γ (PPARγ), uncoupling protein 1 (UCP1), and β-actin or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). WAT paraffin sections (6 µm) were prepared for 
immunohistochemistry with antibodies to detect macrophages (Mac-2), T cells (CD3), 
and FcεR1, and TUNEL staining (In Situ Cell Death Detection Kit, Roche Diagnostics 
Corp) to detect apoptotic cells. We used AlexaFluor conjugated with different 
fluorochromes (Invitrogen) to show localization of FcεR1 to inflammatory cells. All 
antibodies are listed in Supplementary Table 2. 
 
ELISA 
ELISA determined plasma IL6 (eBioscience), monocyte chemotactic protein-1 (MCP-1) 
(eBioscience), IgE (BD Biosciences, Bedford, MA), insulin (Crystal Chem Inc.) and 
serum amyloid A (Life Technologies), according to the manufacturers’ instructions. 
 
2-Deoxyglucose (2DG) uptake assay  
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Preadipocyte 3T3L1 cells were differentiated to adipocytes in a 48-well plate with and 
without IgE (0, 1, 10, 50 µg/ml). After 2 days, glucose uptake was performed using a 2-
deoxyglucose (2DG) uptake measurement kit (Cosmo Bio Co. Ltd., Tokyo, Japan), 
according to manufacturer’s instructions. 
 
siRNA transfection  
Both FcεR1α and scramble control siRNAs (100 nM, Santa Cruz) were transfected to 
preadipocyte 3T3-L1 cells in a 12 well-plate after electroporation with an Amaxa® Cell 
Line Nucleofector® Kit (Lonza, Allendale, NJ). After 24 hours, cells were differentiated 
in an induction medium and cultured for 4 days followed by starvation and stimulation 
with 25 µg/ml IgE for 10 min. Cells were lysed for protein analysis. 
Cell Cytotoxicity assay 
Preadipocyte 3T3-L1 cells were differentiated to adipocytes on an 8-well chamber slide 
or a 96-well plate with and without IgE (50 µg/ml) for 2–8 days before TUNEL staining 
(In Situ Cell Death Detection Kit, Roche Diagnostics Corp.), cell counting kit-8 (CCK-8), 
cell viability assay (Dojindo Molecular Technologies, Inc, Rockville, MD), or lactate 
dehydrogenase cytotoxicity assay (LDH, Promega, Madison, WI), according to the 
manufacturers’ instructions.  
 
Oil-red O staining  
Differentiated 3T3-L1 cells with and without IgE (50ug/ml) in a 96-well plate were fixed 
with 10% formalin for one hour, washed with 100% propylene glycol, and stained with 
0.5% oil-red O for 4 hours. This procedure was followed by washing with 85% propylene 
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glycol. For quantitative analysis, stained cell layers were extracted with isopropanol and 
measured at OD510 nm. 
 
Statistical analysis 
All human data are expressed as means ± SD. Correlation analyses between IgE 
concentration and clinical parameters were performed using Spearman's correlation. 
Regression plots were built after log transformation of IgE values for normalization 
purpose.  All P-values are two-sided, and P-values of <0.05 were considered to be 
statistically significant. All analyses were performed using R software, version 3.0.1. All 
mouse data were expressed as mean ± SEM. Due to our small sample sizes and often 
skewed data distributions, we performed a pairwise non-parametric Mann-Whitney test 
followed by Bonferroni corrections to examine the statistical significance.  
 
Results 
Inverse correlation between human plasma IgE and obesity 
 Data obtained from the 50 obese women (age: 42±11 years, BMI: 50.67±8.26 
kg/m2) showed that serum IgE correlated negatively with BMI (P=0.018, Rho= -0.33) 
(Figure 1A), body weight (P= 0.016, Rho= -0.34) (Figure 1B), and fat mass (P=0.023, 
Rho= -0.34) (Figure 1C). Fasting glycemia, insulin, HbA1C, triglyceride, high-density 
lipoprotein HDL, ApoA1, ApoB, aspartate amino-transferase AST, alanine amino-
transferase ALT, γ-glutamyl transpeptidase γGT, leptin, adiponectin, IL6, and hs-CRP 
did not associate with IgE levels. Only total cholesterol correlated positively with IgE 
(P= 0.028, Rho=0.31) (Supplementary Table 3). Of the 50 severely obese patients, 18 
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had type 2-diabetes. Diabetic obese patients were significantly older and exhibited a 
higher BMI, fasting glycemia, fasting insulin, and HbA1C as expected. These patients 
also had lower HDL and higher triglyceride, ALT, γGT, IL6 and hs-CRP levels than non-
diabetic obese patients. Diabetic and non-diabetic obese patients did not exhibit 
significantly different plasma IgE levels, however (data not shown). 
 
FcεR1 deficiency increases body weight gain, but improves glucose tolerance in mice 
This study monitored the body weight and included glucose and insulin tolerance 
assays in both male and female WT and FcεR1-deficient Fcer1a–/– mice. Male (Figure 
2A) or female (data not shown) FcεR1-deficient Fcer1a–/– mice gained significantly more 
body weight than WT control mice on a HFD. Fcer1a–/– mice consumed significantly 
more food and gained more lean and fat mass, as determined by DEXA analysis (Figure 
2B). Fcer1a–/– mice demonstrated significantly improved glucose tolerance but exhibited 
no difference in insulin tolerance when compared to WT control mice (Figure 2C), 
suggesting that Fcer1a–/– mice had improved glucose metabolism but a similar degree of 
insulin resistance to that of WT mice. Consistently, overnight-fasted Fcer1a–/– mice 
exhibited elevated glucose-induced insulin release, which showed no significant 
difference from WT mice at 90 minutes after the first glucose stimulation (Figure 2D). 
Islets from WT mice released insulin responding to glucose in a dose-dependent manner, 
but IgE did not affect islet insulin production at any tested doses of up to 100 µg/mL 
(Figure 2E). The low level expression of FcεR1 on islets possibly triggered insignificant 
insulin induction responding to IgE. RT-PCR revealed about 6-fold lower FcεR1α 
expression on islets than that on bone marrow-derived macrophages (Figure 2F). Non-
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fasted WT and Fcer1a–/– mice on a HFD showed no difference between the basal levels 
of plasma IgE or insulin (Figure 2G). WAT from Fcer1a–/– mice, however, had 
significantly lower IgE levels than WT mice (Figure 2H). Although a direct comparison 
remains impossible, WAT milieu may have much higher IgE concentrations (about 1,600 
ng per mg WAT protein from WT mice) than the plasma (about 150 ng/mL from WT 
mice). Consistent with increased body weight gain, Fcer1a–/– mice had higher plasma 
serum amyloid A (SAA), IL6, and MCP-1 than WT control mice after consuming a HFD, 
although the difference in MCP-1 levels did not reach statistical significance (Figure 2I). 
Yet data showed significantly fewer Mac2-positive macrophages in both subcutaneous 
adipose tissue (SAT) and visceral adipose tissue (VAT) from Fcer1a–/– mice than those 
from WT control mice (Figure 3A/3B). VAT from Fcer1a–/– mice also contained fewer 
CD3+ T cells than VAT from WT mice (Figure 3C). TUNEL staining also revealed 
significantly fewer apoptotic cells in WAT from Fcer1a–/– mice than in WT mice (Figure 
3D), which possibly contributed to increased body weight gain and body fat mass in 
Fcer1a–/– mice (Figure 2A/2B). Metabolic characterization demonstrated that Fcer1a–/– 
mice on a HFD had lower O2 consumption and CO2 production than WT control mice 
(Figure 3E/3F), although the two groups did not reach statistical significance in regards to 
respiratory exchange ratio (RER) and body heat (Figure 3G/3H). Although Fcer1a–/– 
mice showed more food intake than WT control mice (Figure 2B), their plasma leptin 
levels and WAT adipocyte sizes did not significantly differ (Figure 3I/3J). Reduced 
energy expenditure in HFD-fed Fcer1a–/– mice (Figure 3E/3F) may contribute to 
increased body weight gain in these mice (Figure 2A). Immunoblot analysis 
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demonstrated much lower UCP1 expression in BAT from Fcer1a–/– mice than that from 
WT control mice (Figure 3K). 
 
FcεR1 deficiency in mice affects the expression of molecules involved in WAT 
adipogenesis, apoptosis, and glucose uptake  
Immunoblot analysis (Figure 4A) and immunostaining (Figure 4B) confirmed 
comparable FcεR1 expression in WAT from mice following a chow diet and a HFD. In 
WAT, both Mac2-positive macrophages and CD3-positive T cells all express FcεR1 
(Figure 4C). WAT from HFD-fed Fcer1a–/– mice revealed a significantly enhanced 
expression of phospho(p)-AKT (Figure 4D), supporting the suppressive role of FcεR1 on 
AKT activation (18), which requires the expression and activation of C/EBPα and 
PPARγ (19, 20). Increased AKT activation in WAT from Fcer1a–/– mice led to a 
concurrent increase of C/EBPα and PPARγ expressions (Figure 4E/4F). 
Both C/EBPα and PPARγ participate in the control of adipocyte terminal 
differentiation and maintenance (21, 22) and macrophage apoptosis (23). Reduced 
macrophage and T-cell contents (Figure 3A-3C) and reduced cell apoptosis (Figure 3D) 
in WAT from Fcer1a–/– mice may therefore associate with increased expression of 
C/EBPα and PPARγ (Figure 4E/4F). Immunoblot analysis of the same WAT from WT 
and Fcer1a–/– mice revealed reduced expression of the apoptosis-signaling molecule p-
JNK (24) (Figure 4G) and increased expression of cell apoptosis and necrosis inhibitory 
molecule Bcl2 (25) (Figure 4H), which might also contribute to increased fat mass and 
body weight gain in Fcer1a–/– mice (Figure 2A/2B). Improved glucose tolerance and 
increased release of plasma insulin after a glucose challenge in Fcer1a–/– mice (Figure 
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2C/2D) might also associate with increased PPARγ expression (26, 27). Immunoblot 
analysis revealed significantly increased Glut4 expression in WAT from Fcer1a–/– mice 
(Figure 4I). 
 
IgE suppresses adipogenesis in mice 
Increased fat mass in Fcer1a–/– mice (Figure 2A/2B) and increased expression of 
C/EBPα and PPARγ in WAT from Fcer1a–/– mice (Figure 4E/4F) suggest that IgE 
participates in adipogenesis. WAT from mice on a chow or HFD expressed similar levels 
of FcεR1 (Figure 4A/4B). Data consistently revealed elevated levels of FcεR1 expression 
(all three chains: α, β, and γ) during adipogenesis of preadipocyte 3T3-L1 (Figure 5A). 
Partially differentiated 3T3-L1 cells (2 days) that had increased FcεR1 expression 
(compared with pre-adipocytes) helped treat cells with 50 µg/mL IgE, which revealed no 
differences in FcεR1 (α, β, and γ) expression (Figure 5B) with and without IgE 
stimulation. The addition of different concentrations of IgE (10, 50, and 100 µg/mL) to 
3T3-L1 cells during the first 2 days and the whole duration of 8 days of adipogenesis 
tested IgE participation in adipogenesis. At either treatment, 50~100 µg/mL IgE 
significantly blocked 3T3-L1 adipogenesis, as determined by oil-red O staining (Figure 
5C). IgE inhibited increased expression of C/EBPα and PPARγ after 2 days of 3T3-L1 
differentiation, although IgE-induced PPARγ reduction did not reach statistical 
significance (Figure 5D/5E), likely because cells still existed at an early stage of 
differentiation and C/EBPα acts upstream of PPARγ (28). 
 
IgE activity on 3T3-L1 adipocyte apoptosis and glucose uptake  
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Increased fat mass in Fcer1a–/– mice (Figure 2A/2B) but reduced apoptosis in 
WAT from the same mice (Figure 3D) suggest that IgE participates in inducing adipocyte 
apoptosis. The treatment of 3T3-L1 preadipocytes with IgE during differentiation helped 
test this hypothesis. IgE treatment induced adipocyte apoptosis in a time-dependent 
manner (Figure 6A). At both 6- and 8-day time points, IgE completely suppressed 
adipogenesis, but cell apoptosis reached 7% at the 6-day time point and 45% at the 8-day 
time point, respectively (Figure 6A/6B), suggesting that IgE inhibited adipogenesis 
before inducing apoptosis. Indeed, IgE only induced apoptosis of adipocytes but not 
preadipocytes (Figure 6C). IgE toxicity to the cells did not engender IgE-induced 
adipocyte apoptosis. In 3T3-L1 cells after 2 days differentiation, when cells exhibited 
increased FcεR1 expression (Figure 5A/5B) but no evident apoptosis (Figure 6A), a 
range of IgE concentrations did not affect 3T3-L1 cell viability or cytotoxicity as 
determined by assay of CCK-8 and LDH (Figure 6D/6E). 
Improved glucose tolerance in Fcer1a–/– mice (Figure 2C) increased insulin 
secretion to the plasma from Fcer1a–/– mice after a glucose challenge (Figure 2D), and 
increased Glut4 expression in WAT from Fcer1a–/– mice (Figure 4I), which suggests the 
participation of IgE in inhibiting glucose uptake. This study tested this hypothesis in 3T3-
L1 cells after 2 days differentiation, when 3T3-L1 increased FcεR1 expression (Figure 
5A/5B) but IgE treatment did not induce 3T3-L1 apoptosis (Figure 6A) to interfere with 
glucose uptake. While preadipocytes took up 2-deoxy-D-glucose (2DG) at baseline, as 
determined by measuring intracellular hexokinase-phosphorylated 2DG-6-phosphate 
(2DG6P) (29), differentiated 3T3-L1 cells showed a significant increase in glucose 
uptake. IgE treatment inhibited glucose uptake in a concentration-dependent manner 
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(Figure 6F). A reduced expression of glucose transporters likely mediated IgE-suppressed 
glucose uptake. In differentiated 3T3-L1 cells, IgE reduced the expression of Glut4 and 
its upstream signaling molecule p-AKT (Figure 6G). In differentiated 3T3-L1 cells, the 
silencing of FcεR1 expression with its siRNA, as confirmed by FcεR1 immunoblot 
analysis, increased the expression of both Glut4 and p-AKT, compared with those 
transfected with scrambled control siRNA (Figure 6H). This result establishes that IgE 
suppresses glucose uptake by reducing the expression of glucose transporters. 
 
Discussion 
 This study revealed the dual participation of IgE action in obesity and diabetes, 
which remained consistent to observations from several human studies. Plasma IgE levels 
correlated negatively with BMI among patients with severe asthma (11). Data showed 
that plasma IgE levels also correlated negatively with body weight, BMI, and fat mass 
among severely obese women, although the current study observed a relatively small 
cohort with a power of 0.691 compared with other similar studies (11). However, this is 
the first correlation study linking IgE to obesity without the confounding from asthma or 
other allergic or autoimmune diseases. These human studies point to the role of IgE in 
modulating obesity. We reported previously that human plasma IgE correlated positively 
with type-2 diabetes (12, 13). Interruption of IgE action with an anti-FcεR1 antibody 
delayed the onset of type-1 diabetes in mice (14), suggesting IgE increases plasma 
glucose levels. 
This study also demonstrated that the interruption of IgE action in Fcer1a–/– mice 
increased food intake and reduced energy expenditure (O2 consumption and CO2 
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production), as reflected by reduced UCP1 expression in BAT from the Fcer1a–/– mice, 
without exhibiting significant changes in RER and body heat. These physiological 
changes may contribute to increased body weight gain in these mice. Although previous 
data suggest that high RER and body heat reduce body weight, the presence of diabetes 
may affect such values. In obese humans, non-diabetic patients have lower RMR than 
diabetic patients (30). Increased body weight but improved glucose tolerance in Fcer1a–/– 
mice may trigger insignificant differences in RMR and body heat between WT and 
Fcer1a–/– mice, although this hypothesis merits further investigation. At the molecular 
and cellular levels, however, this study proposed two possible mechanisms by which IgE 
reduced fat mass; one is the C/EBPα and PPARγ pathway. Activation of C/EBPα is a 
prerequisite for PPARγ activation (28). Several signaling pathways can activate C/EBPα, 
including the MAP kinase (e.g. p38 and ERK1/2) (31), the cAMP-associated protein 
kinase-A pathway (32), and the AKT pathway (19, 20). Activation of IgE receptor FcεR1 
activates the MAP kinase pathway, but suppresses AKT activation (18). This study found 
that WAT from Fcer1a–/– mice showed increased p-AKT, C/EBPα, and PPARγ, 
supporting a negative action of IgE on AKT activation, downstream C/EBPα and PPARγ 
(19, 20), and consequent adipocyte differentiation (21, 22). The second mechanism by 
which IgE can influence obesity involves its activity in promoting the apoptosis of 
adipocytes while preadipocytes were fully protected. IgE can furnish survival signals to 
MCs and basophils (1), death signals to macrophages and vascular cells (2), but does not 
affect CD4+ and CD8+ T cell survival or death (3). This study revealed that IgE induces 
adipocyte apoptosis but not preadipocytes. Cell differentiation occurred before apoptosis 
in cultured 3T3-L1 cells. Why IgE promotes survival or apoptosis differently from one 
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cell type to another (1-3) remains unclear. Prior studies show that PPARγ activation 
inhibits monocyte/macrophage migration, accumulation, and apoptosis in atherosclerotic 
lesions (23) and in WAT from HFD-fed mice (33). Reduced PPARγ activation in these 
WAT may contribute to reduced macrophages in WAT from Fcer1a–/– mice. Reduced 
JNK activation in WAT from Fcer1a–/– mice, however, may correlate with reduced 
macrophage accumulation and inflammation in WAT (34), although interrupted FcεR1 
signaling and Syk activation may also directly suppress JNK activation. JNK activation 
contributes to body weight gain and glucose tolerance. The protection of JNK-deficient 
mice from obesity and diabetes occurred in DIO mice (35). Reduced apoptosis and p-
JNK expression in WAT from Fcer1a–/– mice support the role of JNK in regulating 
adipocyte apoptosis (24). Although the signaling pathways that control adipocyte 
apoptosis have considerable complexity, IgE-mediated JNK activation, AKT/Bcl-2 
suppression, and AKT-C/EBPα-PPARγ reduction may all contribute to adipocyte 
apoptosis, a hypothesis that merits further investigation. 
In contrast to the inhibitory effect of IgE on obesity, IgE promotes experimental 
type 2 diabetes. IgE-suppressed p-AKT may directly impair the expression and 
distribution of glucose transporters, such as Glut 4 (36, 37), and indirectly via reduced 
PPARγ expression and activation (38). Therefore, in 3T3-L1 cells, IgE reduced p-AKT 
and Glut4 expression and FcεR1 knockdown by its siRNA increased p-AKT and Glut4 
expression, all of which may explain concentration-dependent suppression of glucose 
uptake in 3T3-L1 cells by IgE. A similar pattern occurred in vivo. FcεR1 deficiency 
increased WAT Glut4 expression. These observations may explain why Fcer1a–/– mice 
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had improved glucose tolerance and glucose-induced insulin release. Figure 7 
summarizes our hypothesis. 
 Several questions remain unresolved. Fcer1a–/– mice consumed more food and 
had lower levels of energy expenditure and BAT expression of UCP1 than WT control 
mice. Although these observations may explain why Fcer1a–/– mice gained more body 
weight than WT mice, the mechanism by which IgE activity controls food uptake and 
energy expenditure remains unknown. Prior studies showed that leptin infusion 
augmented plasma IgE levels in allergen-challenged mice (39), but the absence of IgE 
receptor FcεR1 did not affect plasma leptin levels. Therefore, IgE may control food 
uptake and energy expenditure with mechanisms other than leptin. For example, gut 
microbiota-associated metabolic endotoxemia and inflammation impair food uptake (40, 
41). IgE may reduce food uptake by inducing gut inflammation (42, 43), although this 
study did not test this hypothesis. We further found that Fcer1a–/– mice exhibited 
improved glucose tolerance and glucose-induced insulin secretion, but these mice showed 
similar degrees of insulin resistance and similar basal levels of plasma insulin to those 
from WT control mice. This study did not reveal a direct participation of IgE in 
suppressing glucose-induced insulin secretion in isolated islets, suggesting that elevated 
glucose-induced insulin secretion in Fcer1a–/– mice indirectly participated in IgE (44, 
45). 
 All in vitro experiments in this study used IgE at concentrations (10~100 µg/mL) 
much higher than its physiological concentrations in human or mouse plasma (100~400 
ng/mL). At 10 µg/mL, IgE showed a negligible effect in suppressing adipogenesis and 
weak suppression of glucose uptake. Therefore, this study used 50 µg/mL IgE to 
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demonstrate inhibition of 3T3-L1 cell adipogenesis, promoting adipocyte apoptosis, and 
suppressing Glut4 expression and glucose uptake. The physiological relevance of these in 
vitro experiments remains a key question. As described in our prior studies of 
atherosclerosis and AAAs (3, 4), low plasma IgE levels may not necessarily reflect the 
actions of tissue IgE in situ. The tissue milieu may harbor higher levels of IgE than 
previously surmised. This possibility remains consistent to our observation that each 
milligram of WAT extract from DIO mice contained about 1,600 ng of IgE.  
This study provides the first direct evidence of IgE participation in obesity and 
diabetes, although many observations still remain incompletely understood. As atopic 
diseases can affect certain disadvantaged populations who remain particularly vulnerable 
to obesity and diabetes (8-11, 46, 47), these observations have public health implications 
beyond providing novel mechanistic insight. The results of this study, showing divergent 
actions of IgE on obesity and glucose tolerance, require consideration in the context of 
therapeutic targeting of IgE as well. 
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Figure Legends 
Figure 1. Spearman’s correlations between logarithmized human plasma IgE and BMI 
(A), body weight (B), and body fat mass (C).  
 
Figure 2. FcεR1 deficiency increased obesity but improved glucose tolerance in mice. A. 
Body weight gain of male WT and Fcer1a–/– mice on a HFD. B. DEXA determined food 
intake, whole body lean and fat masses after mice consumed a HFD for 17 weeks. 
Glucose and insulin tolerance test (C) and glucose-induced insulin release (D) from male 
WT and Fcer1a–/– mice after 17 weeks of a HFD. E. Insulin production from islets 
treated with and without different doses of glucose and IgE. Insulin secretion is expressed 
as a percent of the islet insulin content (n=4). F. The mRNA expression levels of FceR1a 
in the islets treated with different doses of IgE (n = 4). Bone marrow-derived 
macrophages were used as positive control. Plasma IgE and insulin levels (G), WAT 
extract IgE (H), and plasma SAA, IL6, and MCP-1 levels (I) from male WT and Fcer1a–
/– mice after 17 weeks of a HFD. The number of mice per group is indicated in the 
parenthesis.  
 
Figure 3. FcεR1 deficiency in WAT macrophage and T-cell accumulation, WAT cell 
apoptosis, and in mouse energy expenditure.  Mac2 immunostaning detected 
macrophages in VAT (A) and SAT (B) and CD3 immunostaining detected total T cells 
(C) from male WT and Fcer1a–/– mice after 17 weeks of a HFD. D. TUNEL staining 
detected apoptotic cells in WAT from the same groups of mice. Area under curve (AUC) 
of O2 consumption volume (E), CO2 production volume (F), respiratory exchange ratio 
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(G), and body heat (H) from both male WT and Fcer1a–/– mice consumed a HFD for 17 
weeks (n=6~8 per group). Representative data are shown to the left (A-C) or right (D-G) 
panels. Plasma leptin levels as determined by ELISA (I), WAT adipocyte size (J), and 
BAT immunoblot analysis detected UCP1 expression (K) in both WT and Fcer1a–/– mice 
consumed a HFD for 17 weeks. The number of mice per group is indicated in the 
parenthesis. 
 
Figure 4. Immunoblot analysis of adipogenesis-associated proteins in WAT from WT 
and Fcer1a–/– mice after 17 weeks on a HFD. FcεR1a immunoblot analysis (A), FcεR1a 
immunostaining (B), and FcεR1a immunofluorescent double staining together with Mac-
2 or CD3 (C) of WAT from mice fed a chow diet and a HFD. Immunoblots or RT-PCR 
determined the expression of p-AKT and total AKT (D), C/EBPα (E), PPARγ (F), p-JNK 
and total JNK (G), Bcl-2 (H), and Glut4 (I) in WAT from WT and Fcer1a–/– mice that 
consumed a HFD. β-Actin immunoblots were used to ensure equal protein loading. Data 
are mean ± SEM of five independent experiments. Representative immunoblots for 
panels B-I are shown to the left. 
 
Figure 5. IgE activity in reducing 3T3-L1 cell adipogenesis. A. RT-PCR determined 
mRNA levels of three FcεR1 chains (α, β, and γ) in 3T3-L1 cells at three time points (0, 
2, and 8 days) during the differentiation. B. RT-PCR determined the expression of FcεR1 
three chains (α, β, and γ) in 3T3-L1 cells differentiated for 2 days with and without 50 
µg/mL IgE. C. Oil-red O staining and quantification of 3T3-L1 cells treated with 
different doses of IgE for the first 2 days or throughout the whole course of 
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differentiation (8 days). Preadipocytes and fully differentiated 3T3-L1 cells without IgE 
treatment were used as negative and positive controls. Representative data are shown to 
the right. RT-PCR determined the mRNA levels of C/EBPα (D), and PPARγ (E) in 3T3-
L1 cells before differentiation and after 2 days of differentiation, meanwhile treated with 
and without 50 µg/mL IgE. Data are mean ± SEM of 3 to 5 independent experiments.  
 
Figure 6. IgE activities in promoting adipocyte apoptosis and suppressing adipocyte 
glucose uptake. A. TUNEL staining and quantification of apoptotic cells in 3T3-L1 cells 
differentiated in the presence and absence of 50 µg/mL IgE for indicated days. 
Representative data are shown to the right. B. Oil-red O staining of the same experiment 
from Day-6 and day-8 experiments of panel A. C. TUNEL staining of preadipocytes and 
fully differentiated adipocyte treated with and without IgE (50 µg/mL) to induce cell 
apoptosis. CCK-8 assay determined cell viability (D) and LDH assay determined 
cytotoxicity (E) of 3T3-L1 cells after two days of differentiation with and without 
different amount of IgE. F. Glucose uptake assay of 3T3-L1 cells after two days of 
differentiation with and without different amount of IgE. Preadipocytes were used as 
experimental negative control. G. Glut4, p-AKT, and total AKT immunoblots of 
differentiated 3T3-L1 cells and treated with and without 50 µg/mL IgE for 30 min. H. 
FcεR1α siRNA- and scramble siRNA-transfected 3T3-L1 cells and differentiated for 4 
days, followed by treatment with 25 µg/mL of insulin or IgE for 10 min. β-Actin 
immunoblots were used for protein loading controls. Data are mean ± SEM of three 
independent experiments. 
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Figure 7. Possible mechanisms of FcεR1-mediated IgE actions in regulating the 
expressions of Glut4, C/EBPα, PPARγ, and Bcl2, and associated pathophysiological 
activities in obesity and diabetes.  
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